Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)

NCT07575932 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07575932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07575932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 11, 2026
Completion date
January 5, 2028
Enrollment
940 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

body weight, nutrition disorders, nutritional and metabolic diseases, obesity, overnutrition, overweight, overweight and/or obesity, overweight or obesity